C1orf116

Across TCGA pan-cancer cohorts, C1orf116 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C1orf116 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C1orf116 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C1orf116 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where C1orf116 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.563	0.277	.002	45	view →
UCEC	DFS	Tertile	All	1.000	0.778	<.001	34	view →
HNSC	OS	Median	III,IV	1.000	0.449	.023	8	view →
LUAD	OS	Quartile	III,IV	0.787	0.232	.016	7	view →
CCRCC	DFS	Median	All	0.844	0.631	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C1orf116–PDAC (DFS)

Open the PDAC breakdown →